Whalesbook
Zydus Lifesciences has received final US FDA approval for verapamil hydrochloride extended-release tablets, a drug for high blood pressure with $24.5 million in US annual sales. This comes as the company reported a strong second quarter, with net profit soaring 39% year-on-year to ₹1,259 crore, driven by robust revenue growth and significant forex gains. The approval bolsters Zydus's portfolio of 428 final approvals in the US market.